A 35-year-old man was diagnosed with psoriatic arthritis treated with methotrexate and
cyclosporine, the latter was then interrupted. Subsequently, etanercept was introduced …

Fee and Kasarskis12 described a 66-yearold-diabetic man who developed facial weakness
and bulbar signs after 6 years of etanercept therapy for rheumatoid arthritis. The patient had …

The article presents a case study of a 51-year old male patient, with diabetes and
hypertension, diagnosed with psoriasis at 40 years and psoriatic arthritis 6 years later. The …

We discuss a case of a 47-year-old man who presented with progressive proximal muscle
weakness of the upper and lower extremities and unstable gait. He had been on etanercept …

Myasthenia gravis (MG) is an autoimmune disease characterised by the presence of
acetylcholine receptor antibodies and by blocking the transmission of the signal in the …

Etanercept is an inhibitor of the pro-inflammatory and immunoregulatory cytokine tumor
necrosis factor-α (TNFα). It has been proved highly effective in the treatment of rheumatoid …

Etanercept is an antagonist of tumor necrosis factor alpha that was developed to treat
rheumatoid arthritis. In this report we present a patient who developed myasthenia gravis …

DEAR EDITOR, Ixekizumab is an anti-IL-17A monoclonal antibody that was first licensed as
a disease modifying treatment for active psoriatic arthritis by the European Medicines …

Ustekinumab is a human monoclonal antibody that targets the p40 subunit of both
interleukin 12 (IL-12) and IL-23 and inhibits their activity. IL-12 and IL-23 have a key role in …

SIR, Psoriasis and PsA share common pathophysiological mechanisms. The mutual role of
Th17 cells is supported by the therapeutic efficacy of ustekinumab, an IL-12/23 mAb, in PsO …